multiplex immunoassays

In the rapidly evolving field of cancer research, understanding the complex interplay between tumors and the immune system is essential for developing effective therapies. Bio-Plex Multiplex Immunoassays, for research use only and powered by Luminex xMAP technology, provide a cutting-edge tool for simultaneously measuring multiple immune biomarkers. Learn how these research tools are paving the way for development of personalized cancer treatments in the future.

Recent advances in chimeric antigen receptor (CAR) T-cell therapy have opened exciting new avenues for the treatment of a variety of malignancies. Cytokine release syndrome (CRS), a powerful immune response to activated CAR T cells, is the primary side effect of CAR T-cell therapy, but existing CRS treatments can make CAR T-cell treatment less effective. In two recent studies, researchers used multiplexed cytokine immunoassays to better understand how CAR T-cell therapy triggers CRS and to identify strategies for early intervention in CRS development.

Discover how researchers are utilizing xMAP Multiplex Immunoassays to monitor biomarkers associated with tubular nephrotoxicity in kidney proximal tubule chips.

In December 2022, a groundbreaking law was passed granting the U.S. FDA the authority to consider data from new alternative methods in the preclinical testing phase for new drug development. Among the new methods are 3D cell cultures that mimic human tissues and organs, known as microphysiological systems (MPS). The new law aims to improve clinical outcomes while decreasing reliance on animal testing. In this article, we discuss MPS and review data showing how they can synergize with Bio-Plex Assays.

In this webinar, see how a Bio-Plex Pro Assay could provide a high-throughput culture-free NT50 determination method for current and future SARS-CoV-2 variants.

Current vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have reduced the severity of the coronavirus disease 2019 (COVID-19). However, the drastic and quick evolution of the virus poses challenges to the development of durable and efficacious therapeutics for vaccine and antibody developers alike. See how the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit speeds up the qualitative measurement of neutralizing antibodies (NAbs) against new SARS-CoV-2 variants, removing a roadblock in COVID-19 therapeutic development.

It is imperative to plan and prepare ahead of time for your research using Bio-Plex Assays to be successful. Good assay planning and preparation reduces mistakes and makes for a stress-free assay run. In this series of short videos, we share some simple steps you can take to make sure your work goes smoothly.

Develop new assays in just one day with the Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit. See how in this webinar.

Bio-Plex Pro SARS-CoV-2 Neutralization Antibody Assays provide reliably measure neutralizing antibodies in less than 3 hours. Watch our webinar to learn more.

Presented by: Daniel Braunschweig, PhD, Proteomics Field Application Scientist Leader

View on demand

This webinar provides an overview of multiplexing technology for research use with mouse samples and highlights the associated benefits to your drug discovery workflow. Specific topics include: